GKWIM
CRSP icon

Gerber Kawasaki Wealth & Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Buy
20,472
+12
+0.1% +$632 0.03% 169
2026
Q1 		$973K Buy
+20,460
New +$1.08M 0.03% 165
2021
Q4 		– Sell
-927
Closed -$103K – 453
2021
Q3 		$103K Buy
+927
New +$116K 0.01% 236

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's CRSP Position: Q2 2026 in Review

Gerber Kawasaki Wealth & Investment Management increased its CRISPR Therapeutics (CRSP) stake by 0.06% in Q2 2026, buying an estimated $632 and bringing the position to 20,472 shares worth $1.12M. The position accounts for 0.03% of the portfolio, ranked #169.

Gerber Kawasaki Wealth & Investment Management first reported a position in CRSP in Q3 2021 and has held it in 3 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Gerber Kawasaki Wealth & Investment Management held 20,472 shares of CRISPR Therapeutics worth $1.12M as of Q2 2026.
  • Gerber Kawasaki Wealth & Investment Management bought 12 CRISPR Therapeutics shares in Q2 2026, an estimated $632.
  • CRISPR Therapeutics made up 0.03% of Gerber Kawasaki Wealth & Investment Management's portfolio in Q2 2026, its #169 holding.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 3 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q2 2026, filed 7 Aug 2026.